SCHEMBL265201

SCHEMBL265201

COc1ccc(N(CCc2ccc(C(F)(F)F)cc2)C(=O)[C@H](N)c2ccccc2OC)cn1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPC1 O15118 1/20 0.39
MAPT P10636 1/20 0.39
LIPE Q05469 1/20 0.38
PPARD Q03181 1/20 0.37
PPARA Q07869 1/20 0.37
FLT4 P35916 1/20 0.37
ITGB1 P05556 1/20 0.37
ITGA4 P13612 1/20 0.37
OXTR P30559 8/20 0.36
HPGD P15428 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
AVPR1A P37288 2/20 0.35
ABCG2 Q9UNQ0 1/20 0.35
TRPM8 Q7Z2W7 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL265200 1.00 TSHR (0.39) TSHRSMN1; SMN2NPC1MAPTLIPE
SCHEMBL265202 1.00 TSHR (0.39) TSHRSMN1; SMN2NPC1MAPTLIPE
SCHEMBL264116 0.89 TACR1 (0.39) NPC1MAPTLIPEPPARDPPARA
SCHEMBL264114 0.89 TACR1 (0.39) NPC1MAPTLIPEPPARDPPARA
SCHEMBL264115 0.89 TACR1 (0.39) NPC1MAPTLIPEPPARDPPARA
SCHEMBL3650089 0.85 PPARA (0.41) PPARDPPARAMEN1KMT2APTGDR2
SCHEMBL3649229 0.85 PTGIR (0.40) PPARDPPARAMEN1KMT2APTGDR2
SCHEMBL3645307 0.85 PPARA (0.41) PPARDPPARAMEN1KMT2APTGDR2
SCHEMBL13925698 0.85 PPARA (0.41) PPARDPPARAMEN1KMT2APTGDR2
Hydrochloric Acid SCHEMBL3645400 0.84 PPARA (0.41) PPARDPPARAMEN1KMT2APTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8133909-B2 Heteroaromatic monoamides as orexinin receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
US-20090312314-A1 HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312314-A1 HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPSR1 TSHR 258/4885SMN1; SMN2 2018/4885NPC1 1723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.